

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: NeuroScientific Biopharmaceuticals Limited
ACN: 102 832 995

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Anton Uvarov
Date of last notice	27 June 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Ms Yulia Uvarova <TECHINVEST NOMINEES A/C> (Spouse)
Date of change	27 June 2025
No. of securities held prior to change	Ms Yulia Uvarova <Techinvest Nominees A/C> (Spouse) 2,000,000 - Ordinary Shares Anton Uvarov 350,000 - Ordinary Shares 1,000,000 – Unlisted options exercisable at \$0.07 expiring 27 June 2028.
Class	Ordinary Shares
Number acquired	2,650,000

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$92,750 (Cash)
No. of securities held after change	Ms Yulia Uvarova <Techinvest Nominees A/C> (Spouse) 2,000,000 - Ordinary Shares Anton Uvarov 3,000,000 - Ordinary Shares 1,000,000 – Unlisted options exercisable at \$0.07 expiring 27 June 2028.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in Placement at \$0.035 (shareholder approval obtained – resolution 8 of the general meeting of shareholders held on 23 June 2025).

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/a
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/a
If prior written clearance was provided, on what date was this provided?	N/a

⁺ See chapter 19 for defined terms.